3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
23
Phase 1
9
Phase 1/2
7
Phase 3
2
Phase NA
1
Phase 4
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Breast Neoplasms
26
Neoplasms
11
Carcinoma, Non-Small-Cell Lung
10
Prostatic Neoplasms
8
Multiple Myeloma
7
Lung Neoplasms
7
Melanoma
6
Stomach Neoplasms
5
Leukemia, Myeloid, Acute
5
Glioma
4
Colorectal Neoplasms
4
Carcinoma, Hepatocellular
4
Tuberous Sclerosis
3
Sarcoma
3
Papillomavirus Infections
3
Neoplasm Metastasis
3
Hematologic Neoplasms
3
Glioblastoma
3
Warts
2
Venous Thromboembolism
2
Thyroid Neoplasms
2
Skin Neoplasms
2
Rectal Neoplasms
2
Polycythemia Vera
2
Pain
2
Ovarian Neoplasms
2
Oligodendroglioma
2
Obesity
2
Neoplasms by Site
2
Myasthenia Gravis
2
Interventions
zanubrutinib
1
talquetamab
1
ibrutinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Waldenstrom Macroglobulinemia
×
90 days
×
Clear all
NCT07474961
2026-03-16
BLOOD-dose
Rigshospitalet, Denmark
Phase 4
Not yet recruiting
400 enrolled